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Biomarkers of Chemical Exposure: State of the Art
Philippe Grandjean,”5 Stanley S. Brown,2 Phil Reavey,3 Donald S. Young4
Environmental toxicology has important implications
for human health, and clinical chemistry is perhaps the
medical discipline most closely related to this area. In
June 1993, the International Federation of Clinical Chem-
istry organized, with the support and involvement of Beck-
man Instruments, Inc., the First Arnold 0. Beckman!
IFCC European Conference on Environmental Toxicology.
The topic for this conference was biomarkers of chemical
exposure, a burgeoning multidisciplinary research area.
“Biomarker” is short for biological marker, used in envi-
ronmental toxicology and related fields to denote a mea-
surement that reflects an event in a biological system,
such as the human body.
The meeting included 16 plenary presentations, all of
which are published in this special issue of Clinical
Chemistry. Sixty posters were selected for exhibition at
the conference, and the organizing committee selected
10 of these for publication as extended abstracts. This
overview is intended as an introduction to the field and
as a summary of conclusions and controversies that
emerged during discussions in plenary and at six round-
table discussion sessions.
Typesof Biomarkers
Usually, three specific types of biological markers are
identified (1). The first is a biological marker of exposure,
or exposure biomarker, that may be an exogenous com-
pound (or a metabolite) within the body, an interactive
product between the compound (or metabolite) and an
endogenous component, or another event related to the
exposure. The second, a marker of effect, may be an endog-
enous component, or a measure of the functional capacity,
or some other indicator of the state or balance of the body
or organ system, as affected by the exposure. Such effect
markers are generally predlinical indicators of abnormal-
ities. The third is a marker of susceptibility, whether in-
herited or induced, which serves as an indicator that the
individual is particularly sensitive to the effect of a xeno-
biotic or to the effects of a group of such compounds. Al-
though the three types of biomarkers may not always be
easily separated, this overview will mainly address issues
related to exposure biomarkers.
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The ideal exposure biomarker should have the follow-
ing characteristics: (i) sample collection and analysis
are simple and reliable; (ii) the biomarker is specific for
a particular type of exposure with a clear-cut relation to
the degree of exposure; (iii) the biomarker reflects a
subclinical and reversible change only; (iv) relevant in-
tervention or other preventive effort can be considered,
if indicated by the biomarker result; and (v) use of the
biomarker is regarded as ethically acceptable.
Research on biomarkers evolved mainly from studies
in environmental and occupational toxicology. Exposure
biomarkers first became useful tools in biological mon-
itoring, especially in occupational health surveillance.
Many biomarkers also became important predictors in
epidemiological studies. Nowadays, biomarker studies
reflect a burgeoning research area at the crossroads of
several disciplines, including clinical chemistry and pre-
ventive medicine.
Biomarker research in general either attempts to pro-
vide further validation for a specific measurement or ex-
plores the potential fields for application of the biomarker.
Validity of Exposure Blomarkers
When assessing the usefulness of a particular expo-
sure biomarker, one must consider three aspects of
validity: analytical, toxicokinetic, and health risk.
Analytical
For optimal analytical quality, standardization is
needed, but the specific requirements vary considerably
between individual toxicants. Major areas of concern in-
dude: preparation of the individual; sampling procedure
and sample handling; and measurement procedure that
encompasses technical factors, such as calibration and
quality assurance procedures, and individual-related fac-
tors, such as education and training of operators.
For documentation of analytical validity and trace-
ability, there are global needs for certain matrix refer-
ence materials with concentrations of toxic substances
or relevant metabolites at appropriate levels. For exam-
ple, reference materials for measurements of solvents in
blood or exhaled air are totally lacking. The importance
of speciation has to be recognized in designing certain
reference materials, e.g., the different forms of arsenic
and the metabolites of xylene.
At the same time, the economics of characterizing and
using reference materials to supplement quality-assur-
ance procedures in general must be considered. Thus, the
achievable quality of results, and the uses to which they
are put, have to be balanced against the added costs of
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quality assurance, induding reference materials, man-
power, and instrumentation. One possibility is to gener-
ate a short list of priority biomarker analyses for which
recommendations for appropriate quality-assurance pro-
cedures and reference materials should be developed.
For biomarkers to be used in population studies or for
diagnostic purposes, the participating laboratories must
have well-documented analytical procedures with defined
performance characteristics and accessible records to al-
low verification of the results. For this purpose, national
and international organizations should generate and im-
plement guidelines for internal and external quality-as-
surance procedures to be used by all laboratories generat-
ing data for assessing human health risks, including
exposure biomarkers. Such guidelines could be based on
documents already available from international associa-
tions, professional societies, and governmental agencies.
Modern methods of analysis may allow separation of
isomers or congeners of organic compounds and deter-
mination of the speciation of metal compounds or isoto-
pic ratios of certain elements. Such advanced techniques
will no doubt gain importance for applications in bio-
marker studies, and the requirements for documenta-
tion of analytical validity are likely to be even more
demanding than at present.
Scientific and clinical journals can accelerate the pro-
cess of development and application of well character-
ized methods by accepting manuscripts only if they give
sufficient and satisfactory data on the reliability of the
biomarker measurements.
Toxicokinetic
Toxicokinetic principles must be applied to define the
proper timeframe(s) represented by the biomarker, i.e., the
extent to which the biomarker measurement reflects past
exposure(s) and accumulated body burden. The degree to
which the biomarker indicates retention in specific body
compartments should also be considered. Peripheral blood is
generally not regarded as a compartment as such, although
it acts as a transport medium between compartments.
Life events, such as reproduction and senescence, may
affect the distribution of a xenobiotic. Slow release from a
“deep” compartment that has accumulated the chemical
substance over a long time period may result in a pro-
tracted “endogenous” exposure of target organs. Studies in
animals have been used to reveal toxicokinetic patterns,
but extrapolation to humans may require confirmatory
studies, e.g., in human volunteers.
Health Risk
For proper interpretation of the measurement result
of an exposure biomarker, the diagnostic validity must
be known, i.e., the translation of the biomarker value
into the magnitude of possible health risks. In this area,
metals serve as a paradigm for biomarker research.
Recent research has demonstrated the complexity and
subtlety of dose-response relationships, with consider-
able difficulty in identifying no-effect levels and there-
fore also in defining tolerable exposures. However, this
kind of research has also illustrated the types of inves-
tigation and the refinements that are necessary to un-
cover the relevant information. For most organic com-
pounds, quantitative associations between exposures
and the corresponding adverse health effects are not yet
available; in many cases, even the primary target or-
gans are not known precisely.
Evaluation of toxicity data and biomarker concentra-
tions in human studies is often complicated by exposure
to mixtures of substances. Although studies in animal
models may provide some guidance in this and other
respects, extrapolation to human toxicity must take into
account the species differences in kinetic parameters,
metabolic pathways, and susceptibility.
Adduct formation between xenobiotics and macromol-
ecules is a promising research area, but the analytical
methods are new, expensive, and need further develop-
ment and validation. They are useful for occupational
monitoring but not yet ready for applications to envi-
ronmental biomonitoring. Simpler analytical methods,
e.g., based on immunological techniques, are needed so
as to reserve current methods as reference procedures.
Especially at low levels of exposure, concurrent expo-
sure to tobacco smoke or other confounding factors may
have a significant impact on the measurement results,
causing severe difficulties in interpretation.
ApplIcatIon of Exposure Blomarkers
Given an acceptable degree of validity, exposure bio-
markers may be used for several purposes. On an individ-
ual basis, a biomarker (usually an exposure biomarker)
may be used to support or refute a diagnosis of a particular
type of poisoning or other chemically induced adverse ef-
fect. In a healthy subject, an exposure biomarker may also
serve as a basis for risk prediction and counseling. Other
types of biomarkers may reflect individual hypersuscepti-
bility to specific chemical exposures; such biomarkers
should be used preventively rather than after the event.
On a population basis, some biomarkers of exposure can be
applied to assess the extent of compliance with pollution-
abatement regulations or effectiveness of preventive ef-
forts in general. The problems and research needs are well
illustrated by some concerns specifically relating to the
use of human milk for biomarker assays.
Contaminants in Human Milk
Among contaminants excreted in human milk, the
persistent compounds have raised special concerns.
However, although the concentrations may be higher
than in other food items, the concentrations found in
milk should be compared to the degree of transpiacental
transfer and to the total lifetime exposures from other
sources. Nevertheless, the rapidly developing infant
may be particularly vulnerable to toxic damage. Thus
far, only limited information is available on metal con-
centrations in milk, particularly methyhnercury. Many
studies are of limited value because risk factors were
not described, and the sampling and analytical protocols
were not properly documented. For comparison pur-
poses, infant formulas should be characterized with re-
gard to their content of major chemical contaminants.
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Human milk is not suitable for monitoring exposure
levels or body burdens in the general population, but anal-
yses of milk contaminants can be useful to determine the
exposures incurred by nursing infants. Monitoring cannot
be recommended as a basis for individual counseling about
breastfeeding, but in some circumstances, women may be
advised during pregnancy and lactation not to consume
certain food items, such as fish from contaminated lakes.
The amounts of chemicals present in human milk are
affected by many factors, including sampling techniques
and maternal characteristics. To obtain the most reliable
result, one should collect samples of mature milk 6-8
weeks post partum. Milk for analysis should be collected
during the second half of a breast-feeding session to min-
imize the variability. Concentrations of lipid-soluble
chemicals should be quantified on a lipid basis. The fol-
lowing information should be collected from each mother:
age, parity, body mass and height, change in body mass
during pregnancy and since parturition, life-style factors
(diet, smoking, alcohol use), socioeconomic status, and fre-
quency and duration of breastfeeding. Because human
milk may contribute multiple chemical exposures, biom-
arkers of integrated effects would be of particular use to
assess the total effect of exposure.
PriorIty Areas for Research
The foregoing considerations regarding validity sug-
gest several areas of importance for biomarker research.
While further documenting the advantages of exposure
biomarkers, the limitations of this approach must also be
kept in mind. Exposure biomarkers may not be at all
useful for some chemicals that are short-lived in vivo;
other means of exposure assessment should be developed.
The route of exposure may also affect the biomarker
measurement result and its interpretation. For example,
direct exposure of the central nervous system via uptake
by the olfactory nerve is likely to escape detection by
measurement of exposure biomarkers in body fluids.
These and other limitations need to be elaborated.
The need for standardization is obvious with regard to
validation of biomarker analyses, but this need is much
less clear-cut with epidemiological issues. Important
concerns include whether the individuals examined are
representative of the exposed population, and whether
data on exposure predictors and health outcome mea-
sures are accurate. Other general standardization needs
include protocols to interpret measurement results and
guidelines for deciding subsequent action.
For the purposes of long-term epidemiological studies,
tissue banks would be useful so that samples can he re-
trieved for analysis of exposure biomarkers at a time when
health outcome measures are known and when more sen-
sitive detection systems and methods may be available.
ApplIcation for Prevention
For preventive purposes, maximum allowable limits for
exposure biomarkers may be useful. Such limits should be
based on the best advice of clinicians and scientists from
appropriate disciplines, and responsible administrators as
“risk managers” should then take into account relevant
ethical, social, cultural, and economic factors. The scien-
tific basis should, if possible, include dose-response rela-
tionships supplemented by information on variations in
susceptibility within the population at risk. In some
countries, workers and members of the general public are
involved in the standard-setting process and provide im-
portant input, particularly when scientific uncertainty is
considerable. One of the major uncertainties is how to
define an adverse health effect that should be prevented,
e.g., whether adduct formation as an exposure biomarker
represents by itself an adverse effect (i.e., effect biomar-
ker) that should be prevented. Difficult questions are
likely to arise when one is deciding whether it is ethically
defensible, for the same compound, to have different lim-
its for adventitious exposure on the one hand and for
occupational exposure on the other.
Ethical Constraints
Our production of scientific data has greatly outdis-
tanced our understanding of the needs to be satisfied
when disseminating and utilizing this information in
the framework of public health. This inconsistency re-
lates in particular to the use of biomarkers in monitor-
ing and surveillance studies.
The information generated by the use of biomarkers
should generally be conveyed to the individuals examined
within the physician-patient relationship. Ethical con-
cerns in particular must be considered in connection with
highly experimental biomarker analyses that cannot cur-
rently be interpreted in detail in terms of actual health
risks; e.g., for the general population, little guidance can
be given at present with regard to interpreting effects of
exposure biomarkers other than the blood-lead concentra-
tion. Also of importance is the confidence in the data gen-
erated, i.e., whether appropriate sampling has been done,
and whether sound quality-assurance procedures have
been used in the laboratory involved. An additional area of
concern relates to individual hypersusceptibility. These
issues must be taken into account when one is providing
feedback from the study.
All sectors of society affected by, or concerned with
carrying out, a biomarker study need to be involved in
the decisionmaking process on how to handle the infor-
mation generated by the study. Specific procedures to
prevent or overcome inevitable ethical conflicts should be
developed within the legal and social frameworks of the
region or country. However, each situation represents a
different set of questions and pitfalls, and no single pro-
cedure for public involvement can be developed to cover
all applications of exposure biomarkers.
This overview is based on notes prepared by the session chairs. We
are grateful te Antero Aitlo, George Becking, Ren#{233}Dybkr, lldiko
Farkas, Joseph Graziano, Birger Heinzow, Masayuki Ikeda, Bany
Johnson, Renate Kimbrough, Erminio Marafante, Carnce Nolan, Pa-
olo Preziosi, Aim Robinson, Eric Sampson, Ellen Silbergeld, Staffan
Skerfving, and Stanislaw Tarkowski for their contribution.
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